-
Valeant's CEO Details The Company's 'Great Progress' And What's Next
Thursday, August 17, 2017 - 11:02am | 390Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company. But since bottoming at $8.31 per share this year, the company has made "great...
-
Biotechs With Upcoming PDUFA Dates
Wednesday, July 18, 2012 - 3:09pm | 871Read More...On Tuesday, the FDA approved the second weight-loss drug in the last 13 years when it green-lighted Vivus' drug Qsymia. On Wednesday, VVUS shares have shot up more than 14 percent to $30.27. The approval of this drug and the excitement that it has created in the biotech investing community may...
